- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02523807
Tremor Monitoring Device
October 30, 2017 updated by: Ilana Schlesinger, Rambam Health Care Campus
Patients with tremor may have varying degrees of tremor at different times.
The amplitude and frequency of tremor may change.
The investigators observational study is intended to document this tremor.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
18
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Patients with tremor due to Parkinson's disease or Essential tremor will be included
Description
Inclusion Criteria:
- Patients with tremor due to Parkinson's disease or Essential tremor
Exclusion Criteria:
- Severe dementia
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Patients with Parkinson's Disease
Patients with tremor due to Parkinson Disease
|
Patients with Essential tremor
Patients with tremor due to Essential tremor
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum linear acceleration of the forearm.
Time Frame: Linear acceleration of the forearm will be measured for 15-60 minutes.
|
We will measure linear acceleration of the forearm in meter per second squared.
|
Linear acceleration of the forearm will be measured for 15-60 minutes.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum angular velocity of the forearm.
Time Frame: Maximum angular velocity of the forearm will be measured for 15-60 minutes.
|
We will measure angular velocityof the forearm in degrees per second.
|
Maximum angular velocity of the forearm will be measured for 15-60 minutes.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Ilana Schlesinger, M.D., Rambam Health Care Campus
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2015
Primary Completion (Actual)
October 30, 2017
Study Completion (Actual)
October 30, 2017
Study Registration Dates
First Submitted
August 10, 2015
First Submitted That Met QC Criteria
August 12, 2015
First Posted (Estimate)
August 14, 2015
Study Record Updates
Last Update Posted (Actual)
October 31, 2017
Last Update Submitted That Met QC Criteria
October 30, 2017
Last Verified
October 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0486-14-RMB
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson's Disease
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
Assistance Publique - Hôpitaux de ParisFrance Parkinson AssociationUnknownHealthy Controls | Parkinson's Disease With LRRK2 Mutation | Parkinson's Disease Without LRRK2 MutationFrance
-
University Hospital, GrenobleCompletedParkinson's Disease (Disorder)France
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
Universidade Federal de PernambucoCompletedParkinson's Disease.Brazil
-
Shanghai East HospitalShanghai iCELL Biotechnology Co., Ltd, Shanghai, ChinaRecruitingIdiopathic Parkinson's DiseaseChina
-
Beijing Tiantan HospitalRecruitingPD - Parkinson's DiseaseChina
-
AbbVieActive, not recruitingParkinson's Disease (PD)United States, Australia
-
AbbVieCompletedParkinson's Disease (PD)United States, Australia
-
BlueRock TherapeuticsMemorial Sloan Kettering Cancer CenterActive, not recruitingAdvanced Parkinson's DiseaseUnited States, Canada